In a filing, CRISPR Therapeutics AG revealed its Chief Executive Officer Kulkarni Samarth unloaded Company’s shares for reported $0.76 million on Aug 18 ’25. In the deal valued at $58.15 per share,13,081 shares were sold. As a result of this transaction, Kulkarni Samarth now holds 207,004 shares worth roughly $11.24 million.
Then, Treco Douglas A bought 20,000 shares, generating $1,140,600 in total proceeds. Upon buying the shares at $57.03, the Director now owns 22,000 shares.
Before that, George Simeon bought 989,812 shares. CRISPR Therapeutics AG shares valued at $51,499,918 were divested by the Director at a price of $52.03 per share. As a result of the transaction, George Simeon now holds 1,730,179 shares, worth roughly $93.98 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Friday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 2.84% to $54.32. Over the last five days, the stock has lost -9.06%. CRISPR Therapeutics AG shares have risen nearly 10.70% since the year began. Nevertheless, the stocks have risen 38.01% over the past one year. While a 52-week high of $71.13 was reached on 07/21/25, a 52-week low of $30.04 was recorded on 04/07/25.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 52.92, which if violated will result in even more drops to 51.53. On the upside, there is a resistance level at 55.40. A further resistance level may holdings at 56.48.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-07-31, dropping by -2.1 million shares to a total of 23.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 25.54 million shares. There was a decline of -8.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
